Glenmark’s arm gets final USFDA’s approval for Esomeprazole Magnesium Delayed-Release Capsules

14 May 2019 Evaluate

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Esomeprazole Magnesium Delayed?Release Capsules USP, 20 mg and 40 mg, a generic version of Nexium Delayed?Release Capsules, 20 mg and 40 mg, of AstraZeneca Pharmaceuticals LP.

According to IQVIA sales data for the 12 month period ending March 2019, the Nexium Delayed? Release Capsules, 20 mg and 40 mg market achieved annual sales of approximately $395.1 million.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

1937.40 -1.95 (-0.10%)
02-Feb-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1628.90
Dr. Reddys Lab 1182.35
Cipla 1313.00
Zydus Lifesciences 877.15
Lupin 2124.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×